AbbVie notched a win late last month in its ongoing battle against thousands of lawsuits that claim AndroGel, a once-blockbuster drug marketed to treat low testosterone in men, causes heart attacks, ...
(Bloomberg) — Abbott Laboratories and AbbVie Inc., the company it spun off last year, hid the dangers of using the testosterone replacement drug AndroGel, five men claimed in lawsuits. Their ...
(Reuters) - A U.S. jury on Thursday ordered AbbVie Inc to pay more than $140 million to a man who claimed the company misrepresented the risks of its testosterone replacement drug AndroGel, causing ...
ABBOTT PARK, Ill., April 29, 2011 /PRNewswire/ -- Abbott (NYSE: ABT) announced today that the U.S. Food and Drug Administration (FDA) has approved AndroGel® (testosterone gel) 1.62%, a clear, odorless ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback